The Senate hearing pertains to Mylan’s $465 million settlement with the government over charges the Canonsburg, Pa.-based drugmaker purposely misclassified EpiPens as a generic drug to underpay federal healthcare programs.
Committee Chairman Sen. Charles Grassley (R-Iowa) was one of several senators to openly criticize the settlement. In October, he sent a letter to U.S. Attorney General Loretta Lynch asking for further information about the settlement and the grace period that does not require Mylan to classify EpiPens as a branded drug under Medicaid’s rebate program until April 2017.
Sen. Grassley is considering filing a subpoena or taking other appropriate actions to force all parties involved to testify, according to ABCNews.
“Unfortunately, because of the unconventional refusal by these three entities to attend, we must now consider compelling their participation,” Sen. Grassley said in the statement. “This committee will not stop until our questions are answered and any appropriate actions are taken.”
More articles on supply chain:
5 trends on the growing role of digitization in supply chain
FDA approves expanded use of Janssen’s Darzalex for multiple myeloma patients
Texas blood center in desperate need of O-negative blood
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.